Physician profile
Lev Davidson
NPI 1487845244
$1,470.61
in general payments reported to CMS, 2019-2025
15 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.95 · 2020: $16.94 · 2022: $165 · 2023: $316 · 2024: $562 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.07 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $683.66 | 2022-2025 | Imfinzi, Tezspire, Enhertu |
| Madrigal Pharmaceuticals | $148.00 | 2025 | Rezdiffra |
| Beigene USA, INC. | $140.00 | 2024 | Brukinsa |
| Merck Sharp & Dohme LLC | $110.52 | 2023-2024 | Keytruda |
| Incyte Corporation | $99.95 | 2024 | |
| Celgene Corporation | $62.75 | 2024 | Reblozyl |
| Janssen Pharmaceuticals, INC | $33.89 | 2019-2020 | |
| Amgen INC. | $33.16 | 2023 | Blincyto, Kyprolis |
| Genzyme Corporation | $29.46 | 2023 | |
| Pfizer INC. | $28.75 | 2024 | |
| Eisai INC. | $23.78 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.78 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $19.29 | 2024 | Onivyde |
| Springworks Therapeutics, INC. | $18.91 | 2024 | Ogsiveo |
| Ge Healthcare | $16.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lev Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.